Cygnal Therapeutics has appointed Pearl Huang to serve as its CEO. Huang most recently worked at Roche, where she was senior vice president and global head of therapeutic modalities. Her experience also includes executive roles at GlaxoSmithKline (NYSE: [[ticker:GSK]]), Merck (NYSE: [[ticker:MRK]]), and BeiGene (NASDAQ: [[ticker:BGNE]]). Cambridge, MA-based Cygnal developed within the labs of venture capital firm Flagship Pioneering over the past two years. The startup is researching “exoneural biology,” developing drugs that target nervous system mechanisms and pathways that play a role in cancer, inflammation, and autoimmune disease.
